SNIPR's CRISPR-Armed Phage Therapy SNIPR001 Demonstrates Safety in First Human Trial
Key Insights
SNIPR Biome (search) published positive Phase 1 results for SNIPR001 in The Lancet Microbe, marking the first randomized, placebo-controlled trial of an orally administered CRISPR-Cas-armed bacteriophage therapeutic.
The study demonstrated favorable safety and tolerability across three dose levels in 36 healthy volunteers, with no serious adverse events and restriction to the gastrointestinal tract without systemic exposure.
SNIPR001 showed a 78% reduction in E. coli (search) levels versus placebo at the highest dose, though the study was not powered for statistical significance on efficacy endpoints.
SNIPR Biome (search) has achieved a significant milestone in CRISPR-based antimicrobial therapy with the publication of positive Phase 1 results for SNIPR001 in The Lancet Microbe. The Copenhagen-based biotech's novel therapeutic represents the first randomized, placebo-controlled trial of an orally administered CRISPR-Cas-armed bacteriophage designed to selectively target Escherichia coli in the gastrointestinal tract while preserving the broader gut microbiome.
First-in-Human Trial Demonstrates Safety Profile
The Phase 1 dose-escalation trial (NCT05277350) enrolled 36 healthy volunteers who received escalating oral doses of 10⁸, 10¹⁰, and 10¹² plaque-forming units twice daily for seven days in a randomized, double-blind, placebo-controlled design. The study's primary focus on safety and tolerability yielded encouraging results across all measured parameters.
No serious adverse events were reported in any SNIPR001 dose groups, and the overall adverse event rates were comparable to placebo. Functional SNIPR001 was recovered from stool in dose-proportional concentrations, while no meaningful detection occurred in plasma or urine, confirming the therapy's restriction to the gastrointestinal tract. Importantly, gut microbiota composition remained stable throughout the dosing period and follow-up, addressing a key concern about preserving beneficial bacteria.
"This study delivered a very clear message on feasibility and safety," said Eric van der Helm, VP Business Development at SNIPR. "In a randomised, controlled first-in-human trial, we showed that orally administered engineered phages are safe and well-tolerated, including at higher doses. This has not been shown before for an orally dosed CRISPR–Cas-armed phage therapeutic, and it sets an important benchmark for the field."
CRISPR Technology Adds Precision to Phage Therapy
SNIPR001's design builds on classical phage therapy by incorporating programmable CRISPR-Cas3 (search) killing mechanisms. The therapeutic combines multiple wild-type lytic phages that bind different bacterial surface receptors, reducing the likelihood of E. coli (search) escape through single mutations. Once inside bacterial cells, the phage expresses CRISPR machinery that degrades the bacterial genome at pre-programmed sites, ensuring cell death even when lysis alone would be insufficient.
This dual-action approach generated fewer resistant survivors in laboratory testing compared to wild-type phages, addressing a critical durability concern for antimicrobial therapeutics. The system targets multiple critical genomic regions simultaneously, making bacterial survival through mutation considerably more difficult.
While the Phase 1 study was not powered for efficacy endpoints, the highest-dose group showed a 78% reduction in E. coli (search) levels versus placebo at day 14, though this did not reach statistical significance. Van der Helm emphasized the context: "The fact that we saw a dose-dependent trend is meaningful to us; it suggests E. coli target engagement and supports the decision to move forward into a phase 1b/2a trial in patients."
Targeting High-Risk Cancer Patients
SNIPR001 addresses a critical unmet need in patients with hematological cancer (search) undergoing hematopoietic stem-cell transplantation (HSCT). These patients face elevated risk of life-threatening bloodstream infections (search) due to neutropenia (search) and gut barrier damage, with E. coli (search) translocation from the intestinal tract representing a major concern. Antibiotic resistance (search) further complicates prevention strategies and limits standard-of-care effectiveness.
The ongoing Phase 1b trial (NCT06938867) is evaluating SNIPR001 in this precise patient population across eight US cancer centers, targeting enrollment of 24 patients. SNIPR announced that recruitment is now more than halfway complete, reflecting strong site engagement and progress toward the intended high-risk population.
"The biology is different," explained Christian Grøndahl, Founder and CEO at SNIPR. "The microbiome of the intended patient population can differ substantially from that of healthy volunteers, and E. coli (search) can be present at much higher abundance. In that context, we expect SNIPR001 to have more dynamic range to demonstrate activity."
Platform Approach to Antimicrobial Resistance
SNIPR001 represents more than a single asset, functioning as validation of a broader platform approach to CRISPR-based antimicrobials. The company has applied similar engineering principles to develop therapeutics against other high-priority bacterial threats, including Klebsiella (search) and Pseudomonas (search) species.
The therapeutic holds FDA fast-track designation for prophylaxis of bloodstream E. coli (search) infections in patients with hematological malignancy at risk of neutropenia (search). This regulatory recognition underscores the significant unmet medical need in this vulnerable patient population, where antibiotic-resistant bacteria were estimated to have directly caused 1.27 million deaths globally in 2019, with E. coli as the single largest contributor.
"We position SNIPR001 primarily as a way to prevent infections from happening in the first place – and we have encouraging data supporting the potential for treating active infection as well," said Grøndahl, highlighting the dual preventive and therapeutic potential of the platform.
The publication in The Lancet Microbe marks a crucial validation point for CRISPR-enabled precision antimicrobial therapy, establishing safety benchmarks for the emerging field while advancing toward efficacy evaluation in the patients who need these innovations most.